iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of “Buy” from Brokerages

iRadimed Corporation (NASDAQ:IRMD) has received a consensus recommendation of “Buy” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $120.00.

IRMD has been the subject of several research reports. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Roth Mkm reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th.

iRadimed Price Performance

NASDAQ IRMD opened at $89.86 on Wednesday. iRadimed has a 12 month low of $55.11 and a 12 month high of $107.90. The firm has a market capitalization of $1.15 billion, a PE ratio of 49.10 and a beta of 0.91. The company’s 50 day simple moving average is $91.71 and its 200 day simple moving average is $95.47.

iRadimed (NASDAQ:IRMD) last released its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The firm had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts anticipate that iRadimed will post 1.52 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s payout ratio is 43.72%.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at approximately $195,922,500. The trade was a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 70,000 shares of company stock worth $6,545,353 over the last ninety days. 36.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IRMD. Farther Finance Advisors LLC boosted its position in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares during the period. Quarry LP purchased a new stake in shares of iRadimed in the third quarter worth approximately $40,000. CWM LLC lifted its position in shares of iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 107 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. Finally, USA Financial Formulas purchased a new position in iRadimed during the fourth quarter valued at approximately $82,000. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.